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The mechanisms of histamine’s effect in cancer are probably
multi-factorial. Some colon cancer cell lines have been shown to
have functional histamine receptors and can be stimulated by local
histamine administration (Adams et al, 1994). Histamine also has
important effects on immune cells and it was noticed that patients
with colorectal cancer receiving pre-resection cimetidine, an H2
antagonist, had a greater chance of having tumour infiltrating
lymphocytes (TIL) in their tumours than did the controls (Adams
and Morris, 1994, 1997). In contrast, a study by our group found
that cimetidine does not influence TIL in breast cancer (Ng et al,
1995). We have reported trends to survival advantage in CR cancer
patients treated perioperatively with cimetidine which reached
significance in replication error negative tumours (Kelly et al,
1999).
Histamine has been demonstrated to mediate growth control
mechanisms in experimental mammary carcinomas, specifically
by acting on certain H2 membrane receptors (Cricco et al, 1994),
and to play a major role in development and differentiation in the
normal rat mammary gland (Davio et al, 1994). Davio et al (1995)
found several cell lines derived from mammary gland and human
breast carcinomas expressed histamine receptors. In the human
mammary gland H1 and H2 binding sites have been demonstrated
in both benign and malignant lesions. However, while all benign
lesions had both H1 and H2 receptors, only 75% of malignant
carcinomas had H2 receptors (Lemos et al, 1995).
A previous study by Reynolds et al (1997) involving some
patients in this trial showed the median histamine content of
tumour specimens was significantly higher than that of the adja-
cent healthy tissue. Whether histamine is produced by the tumour
cells, mast cells or synthesized elsewhere, the source responsible
for the apparent increase in tissue histamine concentration is as yet
unknown.
Tumour cell proliferation is a prognostic indicator in breast
carcinoma (Tubiana and Courdi, 1989; Railo et al, 1993, 1997;
Ferno, 1998, Schauer et al, 1998). The Ki-67 antibody has been
recognized for some years as an appropriate antibody to use for
demonstrating tumour cell proliferation in breast tumours because
it reacts with a nuclear non-histone protein present in all active
parts of the cell cycle but absent in G0 (Gerdes et al, 1991;
Cattoretti et al, 1992; McCormick et al, 1993). In contrast, prolif-
erating cell nuclear antigen (PCNA), another often used prolifera-
tion marker, has a long half-life and may therefore be detected in
cells which have recently left the cell cycle or have been involved
in DNA repair (Thomas et al, 1993).
Using the Ki-67 antibody proliferation index, this study exam-
ines the relationship between tumour-cell proliferation and pre-
operative cimetidine treatment. It also examines the possible
effect of the presence of histamine and mast cells on tumour cell
proliferation in breast cancer.
MATERIALS AND METHODS
Patient selection
Ethical approval for the study was obtained from the Southern
Sydney Area Health Authority. Patients were referred to the trial
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Correspondence to: DL Morriscoordinator (JK) from two surgeons (CM and PS). After providing
informed consent to participate in the trial, patients were random-
ized to receive cimetidine (400mg twice daily for 5 days prior to
surgery) or placebo for the same period. The only exclusion
criterion was no other H2 antagonist to be administered for 2
weeks prior to treatment start. Eleven patients in the cimetidine
group and nine receiving placebo were on antihypertension
medication and, of these, five receiving cimetidine and three
receiving placebo were on ACE inhibitors.
Ki-67 staining and analysis
Immunohistochemistry was performed using a labelled strepta-
vidin–biotin detection system (Dako K0609). Washes were
performed between each step in Tris-buffered saline pH 7.6. Four-
micrometre sections of paraffin-embedded tissue were mounted on
Super Frost Plus slides. The slides were heated at 60°C for 1h
prior to staining. After deparaffinization and rehydration antigenic
sites were retrieved by microwaving the sections in Target
Retrieval Solution (Dako S1700) for 10min. Endogenous peroxi-
dase was blocked with 3% hydrogen peroxide in methanol and
non-specific adherence of the localization antibody was blocked
with 1% skim milk in buffer. For antigen localization sections
were incubated in mouse anti-Ki-67 antibody NCL-Ki67-MMI
(Novocastra Laboratories, Newcastle, UK) at 1/100 dilution for
1h at room temperature. The labelled streptavidin–biotin detec-
tion system, LSAB+, was used according to the manufacturer’s
instructions. Antigen sites were visualized with 3,3-diaminobenzi-
dine (DAB) chromogen (Dako S3000). The sections were counter-
stained with Harris’ haematoxylin, dehydrated through increasing
concentrations of ethanol, cleared in xylene and coverslipped
using DePex mounting medium ready for analysis.
The antigen staining was analysed using Video Pro 32 Image
Analyser. Ten high power (400´magnification) representative
fields were analysed for each slide providing a proliferation index
as a percentage of positive-stained tumour tissue compared to total
tumour tissue.
Mast cell staining and analysis
Four-micrometre paraffin sections were mounted on poly-L-
lysine-coated slides. After deparaffinization and rehydration the
sections were incubated in a solution of 1% toluidine blue O (CI
52040) in 30% ethanol for 20min then differentiated with 0.1%
acetic acid until the background was almost colourless or pale
pink. Sections were then dehydrated, cleared and mounted ready
for analysis. A mean count of 6 high power (400´magnification)
fields near the tumour margin were taken for each slide analysed.
Statistical analysis
Mann–Whitney t-test for non-parametric data and Pearson’s corre-
lation using Prism statistical package.
RESULTS
A total of 81 patients were enrolled in the trial. Of these, 39
received preoperative cimetidine while 42 received placebo. The
age range for patients receiving cimetidine was 31–91 (mean 58)
and placebo 32–83 (mean 59). The histological type of tumour is
shown in Table 1.
Comparisons between cimetidine and control group
No significant difference was found between the tumour cell
proliferation of patients receiving cimetidine treatment and
placebo (Figure 1). The method, materials and results of the hista-
mine assay are published in the paper by Reynolds et al (1998).
There appeared to be some difference in tumour tissue histamine
content between the two groups with that of the group on placebo
being higher than the cimetidine group (Figure 2); however, the
difference was not statistically significant (P= 0.1206). When
tumour proliferation was compared with tumour histological
grade, size, differentiation and lymph node involvement no signi-
ficant differences were found between the two groups.
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Table 1 Histological types of tumour
Histological type Cimetidine group Placebo group
Ductal 32 32
Lobular 1 3
Tubular 2 1
Mucinous 0 1
Mixed 1 3
DCIS 1 1
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Figure 1Comparison of mean proliferation index, measured by Ki-67
labelling, between patients receiving preoperative cimetidine treatment and
those receiving placebo
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Figure 2Comparison of tumour histamine content between patients
receiving preoperative cimetidine (n = 9) and those receiving placebo
(n = 12)General analysis
Mast cell counts were done for patients in which tumour tissue
histamine content data was available (Reynolds et al, 1998) and it
was found that tumour histamine content correlated positively with
mast cell count (r2 = 0.4411, P = 0.0035) (Figure 3).
There was strong positive correlation between proliferation and
grade (P < 0.01, r2 = 0.957), between proliferation and mitotic
score (P < 0.01, r2 = 0.95) and between proliferation and tumour
differentiation (r2 = 1.0). There was no correlation between prolif-
eration and lymph node involvement (P = 0.5416) or tumour cell
histamine content (data not shown). While there was no correla-
tion between proliferation and tumour size overall, when size was
divided into quartiles, tumours with a diameter > 20 mm had
higher proliferation index than those with diameter < 20 mm (t-test
P < 0.0001) (Figure 4).
DISCUSSION
We have found no difference in proliferation index between
control and cimetidine-treated patients which excluded at least a
large direct effect of cimetidine on cellular proliferation in human
breast cancer. There are no previous reports of the effect of cimeti-
dine on the proliferation index of human breast cancer cells.
Although not significant, grade 1 tumours showed a higher prolif-
eration index in patients on placebo than cimetidine; however,
only a small number of patients in the trial had grade 1 tumours
(four cimetidine and five placebo). Statistical differences could not
be seen between proliferation and any of the variables of size,
differentiation and lymph node involvement.
Endogenous histamine is implicated in moderating the growth
of experimental mammary carcinomas, treatment with H2 antago-
nists significantly inhibiting tumour growth and proliferation
(Cricco et al, 1994). Some difference in tumour histamine was
apparent, being generally greater in the patients on placebo
although this did not reach statistical significance. However, the
dose of cimetidine being administered achieves a serum concentra-
tion of 10–6 M within 15 min, which persists for 6 h and has the
potential to reverse the adverse affects of histamine locally
(Adams and Morris, 1997). As tumour histamine was only
measured in a small proportion of the patients (nine cimetidine and
12 placebo), analysis of a larger sample is required to determine
whether preoperative cimetidine affects histamine levels in breast
carcinomas.
Looking at the patients in the trial as one group, a weak positive
correlation was found between tumour histamine content and mast
cell count, suggesting that more of the tumour histamine present is
produced by mast cells than tumour cells. While there is evidence
that mast cells are prognostic both in colorectal and breast cancer
(Bouzubar et al, 1989; Leonardi et al, 1992). Lemos et al (1995)
found that only 75% of breast carcinomas express H2 receptors.
Consequently, while mast cells may play a role in breast tumour
growth as suggested by Aatomaa et al (1993), the absence of H2
receptors in 25% of breast carcinomas limits the effect of H2
antagonists on tumour growth.
The present study suggests mast cells significantly contribute to
the tumour tissue histamine content in breast carcinomas. The
tendency towards lower tumour histamine content in patients
treated with preoperative cimetidine indicates cimetidine may
have an influence on histamine production or mast cell activity.
The role of mast cells in tumour proliferation has been studied
mainly in relation to tumour angiogenesis (Roche, 1985a, 1985b)
or connective tissue matrix lysis (Dabbous et al, 1986, 1991). Mast
cell histamine has received less attention. Woolley et al (1993)
found mast cell products, but not exogenous histamine, increased
proliferation in the breast carcinoma cell line 8701-BC. However,
this cell line does not express H2 receptors.
Positive correlations between tumour cell proliferation and
tumour histological grade and mitotic score have been reported by
Bouzubar et al (1989) and Leonardi et al (1992). Tubiana and
Courdi (1989) noted that in breast tumours proliferation was
significant in relation to prognosis. More recently, proliferation as
demonstrated by Ki-67 labelling has been found to be a useful
prognostic indicator in breast carcinoma being positively corre-
lated with histological grading (Railo et al, 1993, 1997; Ferno,
1998; Schauer et al, 1998) as seen in the present study. While Viehl
et al (1990) found significant correlation between Ki-67 index and
mitotic score, unlike our results and those of Bouzubar et al (1989)
and Veronese and Gambarcorta (1990), they also found positive
correlation with lymph node involvement.
No correlation was seen with proliferation when size was
divided into quartiles in our study but tumours with diameter ≤ 2
cm had a significantly lower proliferation index than those > 2 cm
(P < 0.0001). Veronese and Gambacorta (1990) also found a statis-
tically significant relationship between Ki-67 and tumour size
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Figure 3 Correlation between tumour tissue histamine content and mast
cell count (n = 17)
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Figure 4 Comparison of the mean proliferation index for tumours with a
diameter of 20 mm or less and tumours with a diameter greater than 20 mmwhile Bouzubar et al (1989) who looked at three ranges of size did
not. So relationship with size depends on how it is viewed and is
only significant as the two extremes are compared.
In conclusion, this study excludes a large effect of a short-term
preoperative course of cimetidine on Ki-67 proliferation index in
human breast cancer but reports a clear relationship between
tumour histamine level and mast cell number. To the authors’
knowledge this relationship has not been previously reported.
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